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ABSTRACT Variable exposure to antituberculosis (TB) drugs, partially driven by genetic
factors, may be associated with poor clinical outcomes. Previous studies have suggested
an inﬂuence of the SLCO1B1 locus on the plasma area under the concentration-time
curve (AUC) of rifampin. We evaluated the contribution of single nucleotide polymor-
phisms (SNPs) in SLCO1B1 and other candidate genes (AADAC and CES-1) to interindi-
vidual pharmacokinetic variability in Malawi. A total of 174 adults with pulmonary TB
underwent sampling of plasma rifampin concentrations at 2 and 6 h postdose. Data
from a prior cohort of 47 intensively sampled, similar patients from the same setting
were available to support population pharmacokinetic model development in NONMEM
v7.2, using a two-stage strategy to improve information during the absorption
phase. In contrast to recent studies in South Africa and Uganda, SNPs in SLCO1B1
did not explain variability in AUC0–∞ of rifampin. No pharmacokinetic associations
were identiﬁed with AADAC or CES-1 SNPs, which were rare in the Malawian popula-
tion. Pharmacogenetic determinants of rifampin exposure may vary between African
populations. SLCO1B1 and other novel candidate genes, as well as nongenetic
sources of interindividual variability, should be further explored in geographically di-
verse, adequately powered cohorts.
KEYWORDS tuberculosis, pharmacokinetics, single nucleotide polymorphism,
SLCO1B1, AADAC, CES-1
Although effective chemotherapy for tuberculosis (TB) has been available for severaldecades, cure rates are variable, remaining at 34 to 76% in many countries (1–6).
The traditional view that treatment failure, relapse, and emergence of antimicrobial
resistance are predominantly driven by poor adherence has been challenged by reports
that interindividual variability in pharmacokinetic (PK) exposure to rifampin (RIF) ac-
counts for some unfavorable outcomes, even among patients who do not miss doses
of medication (7).
Existing clinical data show up to 10-fold interindividual variability in the plasma PK
indices of key drugs, especially RIF (8–11). Maximum plasma concentration (Cmax) and
area under the concentration-time curve (AUC) measurements are often reported as
“low,” suggesting that some patients are underdosed according to currently clinical
recommendations. Patient physiology, comorbidities, concomitant medications, and
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dietary intake all inﬂuence drug exposure. However, genetic polymorphisms in drug
metabolizing enzymes and transporters may explain up to 30% of the PK variability for
all drugs (12–14). Although Africans have the highest degree of genetic diversity
worldwide (15) and sub-Saharan Africa accounts for a large proportion of global TB
incidence and mortality, data on the pharmacogenetic determinants of antituberculosis
drug exposure among TB-endemic African populations are sparse.
RIF is believed to be the decisive drug that enables short-course chemotherapy.
Metabolism by hepatic esterases and biliary excretion of RIF occurs after ﬁrst-pass
metabolism and hepatocellular uptake, which may be primarily mediated by organic
anion-transporting polypeptide 1B1 (OATP1B1), the product of the gene SLCO1B1 (16,
17). Reports from South Africa and Uganda suggested that two SLCO1B1 single nucle-
otide polymorphisms (SNPs), rs11045819 and rs4149032, are common in African pa-
tients and associated with reduced RIF plasma exposure (18–20). However, a recent
study from a TB-endemic population in southern India reported lower variant allele
frequency of these SNPs than the prior African work and no genotypic effect on the
pharmacokinetics of RIF (21). More data from a broader range of global settings are
required to assess the effect of SLCO1B1 genetics on rifampin exposure.
Within the hepatocyte, RIF is thought to be metabolized by microsomal hepatic
esterases, which have been incompletely characterized to date. In vitro data have
suggested that the serine esterase arylacetamide deacetylase (AADAC) may mediate
25-deacetylation of rifamycins (22) and that SNPs in the genes encoding hepatic
microsomal AADAC may alter RIF clearance (23). Alternative routes to breaking ester
linkages in RIF metabolism may involve the carboxyesterase (e.g., CES-1 and -2)
enzymes which are relatively abundant in the liver and gut. There are no clinical data
to deﬁne the effect of SNPs in AADAC or CES genes on plasma RIF exposure.
To assess previously described pharmacogenetic effects in a new population, and
evaluate the contribution of unexplored polymorphisms in other key metabolic pro-
cesses, we assessed the impact of critical SNPs in the candidate genes SLCO1B1, AADAC,
and CES-1 on plasma exposure to RIF among Malawian adults with smear-positive
pulmonary TB. To maximize our study size with limited resources in a low-income
setting, participants underwent sparse PK sampling at two time points. Prior intensive
PK data from the same population facilitated use of two-stage population PK methods
to improve information on RIF exposure, particularly during the absorption phase.
RESULTS
The sparsely sampled data set comprised 174 participants. A total of 121 (69.5%)
were male, the median age was 30 years (range, 17 to 61 years), and the median weight
was 52.0 kg (range, 34 to 74 kg). Of these participants, 98 (56.3%) were HIV infected,
with a median CD4 count of 174 cells/l (range, 6 to 783 cells/l). Of 98 HIV-infected
patients, 28 (28.6%) were on antiretroviral therapy (ART) at the time of recruitment. Full
details are provided in Table 1.
The intensely sampled data set used for the ﬁrst stage of pharmacokinetic model-
ﬁtting comprised 47 participants: 24 (52%) were male, the median age was 34 years
(range, 16 to 60 years), and the median weight was 52.5 kg (range, 35.8 to 74.3 kg). Of
the 47 participants, 30 (65%) were HIV infected and 13 (27.7%) were on ART at the time
of recruitment. All participants from both cohorts were black Africans newly diagnosed
with TB at Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi.
In the ﬁrst stage of the PK analysis, performed with the intensively sampled data set
alone, a one-compartment model appeared most appropriate with a transit compart-
ment model best describing the absorption phase (Δ objective function value [OFV] 
111). Interindividual random effects (IIV) were supported for the apparent clearance
(CL/F), apparent volume of distribution (V/F), and absorption mean transit time (MMT).
The second stage of the analysis utilized only the sparsely sampled data set. Due to
the relative lack of information on the absorption phase from this data set, model
parameters relating to absorption were ﬁxed at the values estimated in the ﬁrst stage
of the analysis. Model reﬁnement involved a comprehensive search of the covariates
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available. The inclusion of an allometric scaling weight model decreased the OFV
signiﬁcantly (ΔOFV  7). The only demographic covariate which signiﬁcantly affected
the model ﬁt was sex, with a decrease in the OFV of 10.5 (P  0.01). The ﬁnal model
showed an increase of clearance of 17% in male patients, resulting in a decreased of
average AUC of 3% in males. Full PK parameters of the ﬁnal two-stage RIF model are
included in Tables 2 and 3.
A visual predictive check (VPC) of 1,000 simulated data sets indicated that the ﬁnal
model performed adequately (Fig. 1). The values of RIF AUC0–∞ and Cmax were obtained
using empirical Bayesian estimates of the individual parameters. A predicted RIF
AUC0–∞ was generated for each subject using their estimated CL/F from the ﬁnal model
(dose/[CL/F]  AUC). The median predicted AUC0–∞ was 29.9 g·h/ml, with a range of
19.7 to 63.4 g·h/ml. The median Cmax was 4.8 g/ml, with a range of 1.4 to 10.9 g/ml.
TABLE 1 Demographic and clinical description of cohort
Characteristica Total (n  174)
Age in yrs, median (range) 30 (17–61)
Male, n (%) 121 (69.5)
HIV infected, n (%) 98 (56.3)
CD4 in HIV-infected patients in cells/l, median (range) 174 (6–783)
On ART at baseline if HIV infected, n (%) 28 (28.6)
Wt in kg, median (range) 52 (34–74)
Adherence, n (%)b
Missed no doses 143 (82.2)
Missed 2 doses 10 (5.7)
Missed 2 doses 2 (1.1)
Rifampin/isoniazid dose in mg, n (%)
300/150 2 (1.1)
450/225 113 (64.9)
600/300 59 (33.9)
SLCO1B1 mutations
rs11045819
Wild (CC) 150 (86.2)
Heterozygote (AC) 24 (13.8)
Variant (AA) 0 (0)
rs4149032
Wild (TT) 89 (51.1)
Heterozygote (CT) 59 (33.9)
Variant (CC) 26 (14.9)
AADAC mutations
rs1803155
Wild (GG) 3 (1.7)
Heterozygote (CG) 80 (46.0)
Variant (CC) 91 (52.3)
rs61733692
Wild (TT) 174 (100)
Heterozygote (CT) 0 (0)
Variant (CC) 0 (0)
AADAC haplotype
AADAC*1/*1 3 (1.7)
AADAC*1/*2 80 (46.0)
AADAC*2/*2 91 (52.3)
CES1 mutations
rs12149368
Wild (GG) 173 (99.4)
Heterozygote (CG) 1 (0.6)
Variant (CC) 0 (0)
aART, antiretroviral therapy; SLCO1B1, solute carrier organic anion transporter family member 1B1; AADAC,
arylacetamide deacetylase; CES1, carboxylesterase 1. n, number of patients.
bAdherence data were only available for 155 patients.
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Candidate SNPs in the SLCO1B1, AADAC, and CES-1 loci were assessed. The distri-
bution of alleles at these loci is presented in Table 1. The rs11045819 SLCO1B1 SNP was
rare, existing at an overall frequency of 0.07, while the rs4149032 SLCO1B1 SNP had a
minor allele frequency of 0.32. No subjects possessed the variant rs61733692 AADAC
SNP, while the rs1803155 AADAC SNP had a minor allele frequency of 0.25. Only one
patient was heterozygote for the variant rs121493368 CES-1 SNP. Since the metabolic
action of these genes is believed to be exerted largely during ﬁrst-pass metabolism,
their impact on relative bioavailability (F) was tested, as well as on CL/F. Additive,
dominant, and recessive models of effect were tested for each SNP. The inclusion of
SLCO1B1 genotypes did not signiﬁcantly improve the model ﬁt. The AADAC SNPs and
haplotype, or the CES-1 SNP, did not signiﬁcantly alter the RIF model ﬁt, as would be
anticipated from the very low variant allele frequency in our study population.
DISCUSSION
This study is the ﬁrst pharmacogenetic analysis of antituberculosis therapy from
Malawi, the largest such study to date using a population modeling approach to relate
pharmacogenetic polymorphisms to plasma AUC and the ﬁrst to evaluate the effect of
SNPs in AADAC in this context. The results of our analysis draw attention to the
importance of (i) fully considering SNP diversity within Africa, (ii) the complexity of
TABLE 2 Parameter value estimates for the base model stage 1a
Parameter Typical value %RSE 95% CI
CL/F (liters/h) 19.5 3.9 18.2–20.8
V/F (liters) 27.1 13.9 20.9–33.3
Ka (h1) 0.277 9.8 0.23–0.32
NN 1.5 41 0.09–3.9
MMT (h) 0.326 35 0.05–1.0
Random effects
IIVCL 0.165 15.3 0.12–0.20
IIVV 0.425 27.1 0.25–0.59
IIVMMT 0.0706 75 0.01–1.79
Residual variability
Proportional error (%) 0.23 7.8 0.20–0.26
aCL/F, clearance (F is unknown bioavailability); V/F apparent volume of distribution; Ka, absorption rate
constant; NN, number of transit compartment; MMT, absorption mean transit time; IIVCL, interindividual
variability on clearance; IIVV, interindividual variability on volume; IIVMMT, interindividual variability on
absorption mean transit time. RSE, relative standard error reported. CI, conﬁdence interval.
TABLE 3 Parameter value estimates for the ﬁnal model stage 2a
Parameter Typical value (shrinkage [%]) %RSE 95% CI
CL/F (liters/h) 19.6 12 16.7–22.5
V/F (liters) 23.6 9 17.1–30.1
Ka (h1) 0.277 (FIX)
NN 1.5 (FIX)
MMT (h) 0.326 (FIX)
THETA_sexmale 1.2 13 1.0–1.3
Random effects
IIVCL 0.076 (22) 29 0.033–0.11
IIVV 0.397 (28) 29 0.17–0.63
IIVMMT 0.0706 (FIX)
Residual variability
Proportional error (%) 0.22 12 0.19–0.26
aCL/F, clearance (F is unknown bioavailability); V/F apparent volume of distribution; FIX, value was ﬁxed after
model stage 1; NN, number of transit compartment; MMT, absorption mean transit time; THETA_sexmale,
fractional change in clearance for males; IIVCL, interindividual variability on clearance; IIVV, interindividual
variability on volume; IIVMMT, interindividual variability on absorption mean transit time. RSE, relative
standard error reported.
CI, conﬁdence interval.
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competing metabolic processes, and (iii) recognizing the limitations of observational
pharmacogenetic designs.
A two-stage population PK modeling approach was used to quantify RIF exposure
among adult patients on treatment for pulmonary TB, beneﬁting from the availability
of data from a preexisting, exchangeable population of intensively sampled patients
(24). A sequential rather than simultaneous approach was used to handle all the data
because pharmacogenetic information was unavailable for the intensive data set,
reducing the value of combined modeling with incomplete covariates.
The two-step approach enabled plausible and efﬁcient estimation of plasma AUC
from sparsely sampled participants, which is a more reliable measure of total drug
exposure than a single “peak” concentration at a ﬁxed time after dosing. Plasma AUC
demonstrated up to 6-fold variability between patients, like previous African cohorts.
RIF is a crucial component of the current ﬁrst-line anti-tuberculosis regimen. In general,
AUC/MIC (MIC) is the PK index most closely related to the bactericidal activity of RIF
(25), and a recent South African study reported a threshold of AUC of RIF (13 g·h/ml)
to be an independent predictor of poor outcome (26). Therefore, identifying host
pharmacogenetic factors that inﬂuence the AUC of this key drug may help to identify
individuals at risk of treatment failure and explain differences in treatment outcomes
between populations.
The SLCO1B1 locus encodes an organic anion transporter (OATP1B1) implicated in
the hepatic uptake of several drugs and contains at least 17 nonsynonymous SNPs.
Much interest in Europe has focused on the role of rs4149056 (521TC, *5) in toxicity
of statin therapy (27), while studies in South Africa and Uganda have implicated two
SLCO1B1 SNPs (rs4149032 and rs11045819) in reduced RIF exposure (18–20). However,
in keeping with a recent report from southern India (21), inclusion of these genotypes
did not signiﬁcantly improve the PK model ﬁt for RIF in our study.
There are potential explanations for the discrepant results between SLCO1B1 studies.
The rs4149032 variant allele frequency was higher in South Africa (0.70 to 0.76), where
an association with RIF was reported, than our Malawian study (0.32) or southern India
(0.46) where the results were negative. Similarly, the rs11045819 variant allele fre-
quency was higher in Uganda (0.15) that Malawi (0.07) or India (0.01). Therefore, it is
possible that populations with lower allele frequencies require a larger sample size for
adequate power to detect a pharmacokinetic effect. In addition, while rs11045819 is
believed to be functional (463CA, *4), rs4149032 is an intronic SNP of unclear
functional status which, in European populations, is in strong linkage disequilibrium
with rs11045819 (28). However, these SNPs had a low level of linkage disequilibrium (D=
FIG 1 Visual predictive check for the ﬁnal rifampin model. The lower, middle, and upper lines are the 5th
percentile, the median, and 95th percentile for the observed data, respectively. The shaded areas are the
95% conﬁdence intervals for the 5th percentile, the median, and the 95th percentile for the simulated
data.
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0.16) in Malawi, echoing ﬁndings from South Africa (18) and southern India (21). There
are large differences in linkage disequilibrium worldwide and within Africa (15), so it is
possible that previously recognized SNPs may tag functional genes in some popula-
tions but not others.
AADAC, a microsomal serine deacetylase expressed mainly in the liver and gastro-
intestinal tract, is responsible for 25-deacetylation of rifamycins in vitro (23). Previous
preclinical studies identiﬁed that expression of the AADAC*3 allele (rs1803155/
rs61733692) signiﬁcantly reduced RIF clearance (22). No subjects in our study possessed
the AADAC*3 allele, and inclusion of AADAC haplotype did not signiﬁcantly improve the
RIF model ﬁt. Although the low incidence of these AADAC SNPs excluded their role in
explaining interindividual PK variability in this Malawian population, these genes are
understudied. Similarly, the low incidence of one CES-1 SNP in our population does not
exclude the possibility that polymorphisms in this gene are relevant in other popula-
tions or that other mutations are important. Future work may describe higher SNP
incidence in other settings, or identify alternative SNPs of relevance to drug exposure.
The gene loci assessed here focused on hepatic drug uptake and metabolism.
Additional processes, including widely distributed mucosal P-glycoprotein transporters
(29) and orphan nuclear receptor regulatory elements which inﬂuence gene induction
(30) may also inﬂuence RIF metabolism. Investigation of these broader pharmacoge-
netic factors may be studied separately.
These data indicate that interindividual variability in RIF PK among Malawian adults
was not explained by polymorphisms in the candidate genes studied. They illustrate
the importance of local ethnic background in the context of high SNP diversity within
Africa and emphasize the need for caution in extrapolating ﬁndings across the conti-
nent. Growing recognition of the extent and clinical consequences of variable RIF PK
(31–37), coupled with recent evidence that dose escalation is safe and tolerable (38),
highlights the need for ongoing work to better deﬁne the relative importance of
polymorphisms and nongenetic risk factors for low antibiotic exposure in a range of
populations.
There were several limitations to our study. Standard ﬁxed-dose-combination (FDC)
tablets were used in treatment of the participants under ﬁeld conditions, but we have
not been able to account for the effect of quality of the potentially varying drug
formulation on PK variability between the two cohorts. This reﬂects the reality of the
TB drug supply chain in most countries. The use of sparse PK sampling at three ﬁxed
time points over 6 h limited the precision of the estimates in each model, partic-
ularly for the absorption parameters. The use of data from a similar, intensively
sampled cohort to develop a population PK model mitigated this to some extent,
achieving reasonable precision for the key PK parameter, i.e., AUC. Finally, the size
of the data set was not predicated on this secondary pharmacogenetic analysis, and
the negative ﬁndings could be due to a relative lack of power. However, our study
was larger than any reported African cohort to date, and there are limitations on the
number of PK proﬁles, even based on sparse sampling protocols, that can practically
be obtained in the ﬁeld situation. On the other hand, it is widely recognized that
candidate gene studies can be prone to chance ﬁndings which may not be
subsequently replicated.
In conclusion, the high interindividual variability in plasma exposure to RIF among
Malawian adults with pulmonary TB cannot be explained by genetic heterogeneity in
SLCO1B1, as suggested from other African populations. Similarly, the variability cannot
be explained by the novel candidate gene SNPs in AADAC and CES-1 that were
evaluated, but the low frequency of variant genes in our population does not exclude
an association elsewhere. The true signiﬁcance of pharmacogenetic inﬂuences on
disposition of antituberculosis drugs compared to nongenetic factors may only be
established through consistent observation across geographically diverse and ade-
quately powered cohort studies.
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Ethics. Ethical approval was obtained from the College of Medicine Research Ethics
Committee, University of Malawi, and the Research Ethics Committee of Liverpool
School of Tropical Medicine.
MATERIALS AND METHODS
Study participants. The sparse pharmacokinetic data sampling was conducted within a prospective
cohort study conducted at QECH in Blantyre, Malawi, from 2010 to 2012. Consenting adults aged 16 to
65 years with sputum smear-positive pulmonary TB were eligible. Exclusion criteria included a hemo-
globin level of 6 g/dl, a creatinine level of 177 mol/liter, a total bilirubin level of 51 mol/liter, an
alanine transaminase level of 200 IU/liter, a clinical status suggestive of imminent mortality (World
Health Organization [WHO] performance score of 4 [39]), pregnancy, TB treatment within 5 years,
corticosteroid therapy, or baseline resistance to rifampin and isoniazid determined using a GenoType
MTBDRplus 2.0 line probe assay (Hain Life Sciences). Patient characteristics have been reported previ-
ously (40). Participants received daily FDC tablets according to a WHO-approved weight-adjusted
regimen (including rifampin at 8 to 12 mg/kg) and standard National Tuberculosis Programme guidelines
(41). Adherence was monitored by direct questioning and pill counts. All patients had point-of-care HIV
serology. ART was provided in accordance with national protocols.
The intensively sampled pharmacokinetic data used for the ﬁrst stage of model construction was
obtained from a prior study of adult patients with sputum smear-positive pulmonary TB at the same
hospital, conducted from 2007 to 2008. The recruitment criteria, patient characteristics, and treatment
protocols have also been reported previously (24) and were similar to the sparse sampling data set.
Genotyping. Genomic DNA extraction and genotyping were performed from whole blood samples
collected at baseline from each patient, as previously described (18). TaqMan real-time PCR using
ﬂuorescent probes for allelic discrimination was used to detect SNPs of two RIF-transporting or
-metabolizing genes: SLCO1B1 (rs11045819 and rs4149032) and AADAC (rs1803155 and rs61733693).
These SNPs are previously reported to have functional signiﬁcance for RIF PK (18, 22, 23). An exploratory
SNP (rs12149368) in CES-1 was also assessed.
Drug plasma concentration determination. For the sparse sampling cohort, blood collections to
measure steady-state RIF concentrations were undertaken on day 14 or 21 after TB treatment initiation.
Patients attended the study clinic at 7:30 a.m. after an overnight fast. Samples were collected predose
and then again 2 and 6 h after administration of the medications. Plasma was separated by centrifugation
and stored at 70°C until analysis.
RIF concentrations were determined using a liquid chromatographic/tandem mass spectrometry
method (24) using appropriate internal standards validated to internationally recognized acceptance
criteria as previously described (42). The lower limit of quantiﬁcation (LLQ) was 0.5 g/ml for RIF. A total
of 5% of the samples had RIF results below the LLQ. These data points were handled by imputing a value
which was 50% of the LLQ.
Population pharmacokinetic analysis. A population PK model for RIF was developed using
NONMEM (version 7.2.0; ICON Development Solutions). Since the sparse sampling data contained little
information on RIF absorption, a two-stage model-building strategy was used.
In the ﬁrst stage, a data set previously obtained from 47 adult tuberculosis patients in Blantyre
employing intensive sampling, and the same drug assay (24) was used to characterize the absorption
phase. No covariates were included. One- and two-compartment models with alternative models of
absorption were ﬁtted to the data using the ﬁrst-order conditional method of estimation with interaction.
Among the models explored were simple ﬁrst-order absorption or a sequence of zero- and ﬁrst-order
absorption incorporating either lag times or transit compartment absorption. Proportional, additive, and
combined proportional and additive error models were considered to describe residual variability. The
minimal OFV (equal to 2 log likelihood) was used as a goodness-of-ﬁt metric, with a decrease of 3.84
corresponding to a statistically signiﬁcant difference between models (P  0.05, 2 distribution, one
degree of freedom). Residual plots were also examined.
Once the appropriate structural model was established, the values of the absorption parameters were
ﬁxed, and a second-stage analysis was performed using data from the sparsely sampled participants of the
present study. The following covariates were explored: body weight, age, gender, HIV status, and SNP
genotypes.
Exponential errors following a log-normal distribution were assumed for the description of interin-
dividual variability in pharmacokinetic parameters, as shown in the following equation:
xi x expxi (1)
where xi is pharmacokinetic parameter “x” of the ith individual, x is the population parameter estimate,
and xi is the log interindividual variability for parameter “x” drawn from a normal distribution with a
mean of zero and variance 	2. RIF was administered orally, CL and V represent apparent values (CL/F and
V/F, respectively, where F is the oral bioavailability, which was ﬁxed to 1). An allometric weight model was
applied to standardize the pharmacokinetic parameters using a standard weight (wtstd) of 70 kg. An
allometric weight model for clearance parameters is given by CL/Fwt  (wt/wtstd)3/4 and for volume
parameters is given by V/Fwt  (wt/wtstd)1, where CL/Fwt and Vwt are the weight functions for the
clearance parameters and the volume of distribution parameters, respectively, and wt is the individual
weight value.
Dichotomous covariates were introduced as a power model and continuous variables were modeled
using a power model with normalized covariate:
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i 1 COVx (2)
i 1 COVi ⁄ COVmedianCOV (3)
where i is the pharmacokinetic parameter of the ith individual and 1 is the population parameter
estimate. In equation 2 (dichotomous covariates), cov is the ratio value of i for the individuals x 
0 or 1. In equation 3 (continuous covariates), COVi is the value of the covariate for the ith
individual, COVmedian is the median value, and cov is the fraction of i relative to the considered
covariate effect.
Genotype information was coded as an index variable, shown below for CL/F: TVCL  0  1·X1 
2·X2, where 0 is the typical value of CL/F for individuals with homozygosity, 1 is the relative difference
in CL/F for heterozygous for the mutant allele when X1  1, and 2 is the relative difference in CL/F for
patients homozygous for the mutant allele when X2  1.
Graphical methods were used to explore the relationship of covariates versus individual predicted
pharmacokinetic parameters. Each covariate was introduced separately into the model and only retained
if inclusion in the model produced a statistically signiﬁcant decrease in the OFV of 3.84 (P  0.05). A
backward elimination step was then carried out once all relevant covariates were incorporated, and
covariates were retained if their removal from the model produced a signiﬁcant increase in the OFV
(6.63 points; P  0.01, 2 distribution, one degree of freedom).
To perform a VPC using Perl-speaks-NONMEM (PsN), 1,000 data sets were simulated using the
parameter estimates deﬁned by the ﬁnal model with the SIMULATION SUBPROBLEMS option of NON-
MEM. From the simulated data, 90% prediction intervals (P5 of P95) were constructed. Observed data
from the original data set were superimposed for both regimens. PsN was used to run a nonparametric
bootstrap of 200 iterations to provide unbiased estimates of the standard errors and the 95% conﬁdence
intervals of the estimated parameters. Estimates of AUC0–∞ for RIF were calculated from simulated values
of CL/F by using the following equation: AUC0–∞  [(dose  milligrams)/(CL/F)].
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